Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer

Cancer Science

Volumn 104, Issue 12, 2013, Pages 1640-1646

  Zhao, Lu ^a   Yasumoto, Kazuo ^a   Kawashima, Atsuhiro ^b   Nakagawa, Takayuki ^a   Takeuchi, Shinji ^a   Yamada, Tadaaki ^a   Matsumoto, Kunio ^a   Yonekura, Kazuhiko ^c   Yoshie, Osamu ^d   Yano, Seiji ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KANAZAWA MEDICAL CENTER   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TAS 115; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES FLUID; CARCINOMATOSIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTRACELLULAR SIGNALING; MALIGNANT ASCITES; MOUSE; NONHUMAN; PATHOGENESIS; PERITONEAL CARCINOMATOSI; PERITONEUM CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCIRRHOUS GASTRIC CANCER; STOMACH CANCER; THERAPY EFFECT; WESTERN BLOTTING;

ADENOCARCINOMA, SCIRRHOUS; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FIBROBLASTS; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PERITONEAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; STROMAL CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84889588919     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12301     Document Type: Article

References (25)

1. Duarte I, Llanos O. Patterns of metastases in intestinal and diffuse types of carcinoma of the stomach. Hum Pathol 1981; 12: 237-42.
2. Maehara Y, Moriguchi S, Kakeji Y et al. Pertinent risk factors and gastric carcinoma with synchronous peritoneal dissemination or liver metastasis. Surgery 1991; 110: 820-3.
3. Takahashi I, Matsusaka T, Onohara T et al. Clinicopathological features of long-term survivors of scirrhous gastric cancer. Hepatogastroenterology 2000; 47: 1485-8.
4. Huang TJ, Wang JY, Lin SR, Lian ST, Hsieh JS. Overexpression of the c-met protooncogene in human gastric carcinoma - Correlation to clinical features. Acta Oncol 2001; 40: 638-43.
5. Inoue T, Kataoka H, Goto K et al. Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissues. Cancer Sci 2004; 95: 803-8.
6. Trusolino L, Berrotti A, Comoglio PM. MET signaling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834-48.
7. Tsugawa K, Yonemura Y, Hirono Y et al. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology 1998; 55: 475-81.
8. Graziano F, Galluccio N, Lorenzini P et al. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 2011; 29: 4789-95.
9. Fischer OM, Giordano S, Comoglio PM, Ullrich A. Reactive oxygen species mediates Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem 2004; 279: 28970-8.
10. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 1992; 189: 227-32.
11. Okamoto W, Okamoto I, Arao T et al. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther 2012; 11: 1557-64.
12. Lennerz JK, Kwak EL, Ackerman A et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011; 29: 4803-10.
13. Janjigian YY, Tang LH, Coit DG et al. MET expression and amplification in patients with localized gastric cancer. Cancer Epidermiol Biomarkers Prev 2011; 20: 1021-7.
14. Amemiya H, Kono K, Itakura J et al. c-Met expression in gastric cancer with liver metastasis. Oncology 2002; 63: 286-96.
15. Park WS, Oh RR, Kim YS et al. Absence of mutations in the kinase domain of the Met gene and frequent expression of Met and HGF/SF protein in primary gastric carcinomas. APMIS 2000; 108: 195-200.
16. Montesano R, Matsumoto K, Nakamura T, Orci L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 1991; 67: 901-8.
17. Green LM, Reade JL, Ware CF. Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J Immunol Methods 1984; 70: 257-68.
18. Yasumoto K, Koizumi K, Kawashima A et al. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res 2006; 66: 2181-7.
19. Yasumoto K, Yamada T, Kawashima A et al. The EGFR ligands amphiregulin and heparin-binding EGF-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer. Clin Cancer Res 2011; 17: 3619-30.
20. Bhargava M, Joseph A, Knesel J et al. Scatter factor and hepatocyte growth factor: activities, properties, and mechanism. Cell Growth Differ 1992; 3: 11-20.
21. Nakagawa T, Tohyama O, Yamaguchi A et al. E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci 2010; 101: 210-5.
22. Bergethon K, Shaw AT, Ou SH et al. Ros1 rearrangements define a unique molecular class of lung cancer. J Clin Oncol 2012; 30: 863-70.
23. Zou HY, Li Q, Lee JH et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007; 67: 4408-17.
24. Chi AS, Batchelor TT, Kwak EL, Clark JW, Wang DL. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. J Clin Oncol 2012; 30: 30-3.
25. Ou SH, Kwak EL, Siwak-Tapp C et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011; 6: 942-6.